Zenas BioPharma Targets Q2 BLA Filing with 56% Flare Reduction and $3–4B Market
Zenas BioPharma’s INDIGO Phase 3 study in IgG4-RD showed obexelimab cut flare risk by 56% (hazard ratio ~0.4) with 75% flare-free patients and 92% six-month OLE durability. Company aims for U.S. BLA in Q2 and European filing in H2, targeting syringe and autoinjector launches and a $3–4 billion U.S. market.
1. Phase 3 INDIGO Efficacy and Durability
Zenas BioPharma’s INDIGO Phase 3 study in IgG4-RD delivered a 56% reduction in time to disease flare (hazard ratio ~0.4) with roughly 75% of patients remaining flare-free in the primary analysis. In the open-label extension, 92% of evaluable patients remained flare-free at six months with serious adverse events comparable to placebo.
2. Regulatory Filing Timelines and Launch Strategy
The company plans a U.S. BLA submission in Q2 and a European filing in H2, with initial launches using prefilled syringes followed by an autoinjector within a year. A U.S. commercial organization of approximately 70 employees is intended to support market rollout.
3. Commercial Opportunity and Market Research
Market research involving 80 clinicians showed 64% likely to prescribe obexelimab and assigned it a 47% three-year share versus competitors. Zenas BioPharma estimates about 20,000 diagnosed U.S. patients and a $3–4 billion opportunity, projecting obexelimab could exceed $1 billion in peak annual sales.
4. Safety Profile and Administration Preferences
Safety data indicated serious adverse events and infection rates were not higher than placebo, with injection-site reactions similar to control. Surveyed clinicians and patients demonstrated a strong preference for weekly subcutaneous dosing over six-month IV infusions.